Zobrazeno 1 - 10
of 58
pro vyhledávání: '"Yuequan Shi"'
Publikováno v:
BMC Cancer, Vol 24, Iss 1, Pp 1-9 (2024)
Abstract Background The present study aimed to investigate physicians’ perspectives on the diagnosis and treatment decisions for patients with non-small cell lung cancer (NSCLC) harbouring epidermal growth factor receptor (EGFR) exon 20 insertion (
Externí odkaz:
https://doaj.org/article/b1ae1466d33e420d8c2049daf1d40efe
Autor:
Zhanquan Lei, Yuequan Shi, Yiqun Liu, Bo Gao, Kongfeng Shao, Xijin Lin, Lizhen Wu, Zhaojie Yao
Publikováno v:
Frontiers in Oncology, Vol 14 (2024)
ObjectiveTo assess the positional reproducibility of sedated and non-sedated pediatric tumor patients during radiotherapy through a retrospective analysis of cone-beam computed tomography (CBCT) and planned computed tomography (CT) scan data.MethodsT
Externí odkaz:
https://doaj.org/article/84effe5a80454a01bfffba8a013501fe
Autor:
Haoran Zhang, Dongming Zhang, Jia Liu, Yuequan Shi, Xiaoyan Liu, Minjiang Chen, Wei Zhong, Jing Zhao, Yan Xu, Mengzhao Wang
Publikováno v:
Thoracic Cancer, Vol 14, Iss 32, Pp 3191-3201 (2023)
Abstract Background DNA damage response (DDR) pathways are essential to sustain genomic stability and play a critical role in cancer development and progression. Here, we investigated the profile of DDR gene mutations in early‐stage non‐small cel
Externí odkaz:
https://doaj.org/article/6cfb0de24fa641809786fad085b8d0c5
Autor:
Qing Zhou, Xiangning Liu, Ji Li, Bing Tong, Yan Xu, Minjiang Chen, Xiaoyan Liu, Xiaoxing Gao, Yuequan Shi, Jing Zhao, Wei Zhong, Mengzhao Wang
Publikováno v:
Thoracic Cancer, Vol 14, Iss 5, Pp 470-478 (2023)
Abstract Introduction This study investigated whether programmed death‐ligand 1 (PD‐L1) expression of circulating tumor cells (CTCs) in peripheral blood can serve as a predictive biomarker for immunotherapy efficacy in patients with advanced non
Externí odkaz:
https://doaj.org/article/33ac306df8ef419f88997f9415254a1d
Autor:
Yan Xu, Yanjun Song, Xiaoyan Liu, Yuequan Shi, Yingxian Liu, Hao Qian, Xiaoxing Gao, Minjiang Chen, Ruili Pan, Jing Zhao, Wei Zhong, Wei Wu, Mengzhao Wang
Publikováno v:
Cancer Communications, Vol 42, Iss 9, Pp 902-905 (2022)
Externí odkaz:
https://doaj.org/article/a7e600160589423694d54a4ab1bb0052
Publikováno v:
Chinese Journal of Lung Cancer, Vol 25, Iss 7, Pp 460-467 (2022)
Adenosine is a metabolite produced abundantly in the tumor microenvironment, dampening immune response in inflamed tissues via adenosine A2A receptor (A2AR) which is widely expressed on immune cells, inhibiting anti-tumor immune response accordingly.
Externí odkaz:
https://doaj.org/article/02e6e2511cd74d28b9dde47c15fec9a5
Publikováno v:
BMC Pulmonary Medicine, Vol 22, Iss 1, Pp 1-9 (2022)
Abstract Background Less is known about the risk factors for acute respiratory distress syndrome (ARDS) in sepsis patients diagnosed according to sepsis 3.0 criteria. Moreover, the risk factors for ARDS severity remain unclear. Methods We retrospecti
Externí odkaz:
https://doaj.org/article/6ecd4ccfeeac4f03a520368dde0bb6b3
Autor:
Yuequan Shi, Jian Fang, Chengzhi Zhou, Anwen Liu, Yan Wang, Qingwei Meng, Cuimin Ding, Bin Ai, Yangchun Gu, Yu Yao, Hong Sun, Hui Guo, Cuiying Zhang, Xia Song, Junling Li, Bei Xu, Zhiqiang Han, Meijun Song, Tingyu Tang, Peifeng Chen, Hongmin Lu, Yongjie Shui, Guangyuan Lou, Dongming Zhang, Jia Liu, Xiaoyan Liu, Xiangning Liu, Xiaoxing Gao, Qing Zhou, Minjiang Chen, Jing Zhao, Wei Zhong, Yan Xu, Mengzhao Wang
Publikováno v:
Thoracic Cancer, Vol 13, Iss 3, Pp 412-422 (2022)
Abstract Background Immune checkpoint inhibitors (ICIs) are the standard treatment for advanced lung cancer, but immune‐related adverse events (irAEs) remain poorly understood, especially in a real‐world setting. Methods A multicenter observation
Externí odkaz:
https://doaj.org/article/c5bf6538bfd04a4cb230f7fdea6625ff
Autor:
Yuequan Shi, Xiaoyan Liu, Juan Du, Dongming Zhang, Jia Liu, Minjiang Chen, Jing Zhao, Wei Zhong, Yan Xu, Mengzhao Wang
Publikováno v:
Thoracic Cancer, Vol 13, Iss 2, Pp 219-227 (2022)
Abstract Background Pretreatment and on‐treatment plasma cytokine levels in predicting clinical benefit in patients with advanced non‐small cell lung cancer (NSCLC) treated with anti‐programmed death‐1 (PD‐1)‐based chemotherapy is still a
Externí odkaz:
https://doaj.org/article/d265ce711a45414dad71a1dbf36bc087
Autor:
Yuequan Shi, Ji Li, Minjiang Chen, Hongsheng Liu, Dongjie Ma, Yuxiao Lin, Mengzhao Wang, Yan Xu
Publikováno v:
Thoracic Cancer, Vol 12, Iss 24, Pp 3433-3436 (2021)
Abstract Neoadjuvant chemoimmunotherapy has demonstrated improved efficacy and prognosis in stage IIa–IIIb patients with non‐small cell lung cancer (NSCLC). Drug‐induced sarcoidosis‐like reaction (DISR), an autoimmune reaction, has been repor
Externí odkaz:
https://doaj.org/article/9612d0f9772a4662941fa49d815e39a1